From a Patient’s Tumor to a Model for Discovery
A promising new cancer treatment can look great in a laboratory dish.
But cancer is far more complicated inside a living body.
Before a potential therapy can move closer to patients, researchers need to understand how a tumor responds in a biological environment where questions about effectiveness, dose, toxicity and drug combinations can be studied.
That is where the Xenograft & Cell-Lines Core at the Greehey Children’s Cancer Research Institute plays a critical role.
What Is a Patient-Derived Xenograft?
A patient-derived xenograft, or PDX, begins with tumor tissue obtained from a patient with appropriate consent and regulatory oversight.
A portion of that tumor can be implanted into a specially bred mouse whose immune system allows the human tumor to grow.
Researchers can then maintain and study the tumor through generations of these models.
Why go through all that work?
Because a PDX gives scientists another way to study how a real human tumor behaves — and how it responds when researchers challenge it with potential treatments.
It helps bridge an important gap between discoveries made in the laboratory and therapies that may eventually be considered for clinical testing.
Putting Potential Treatments to the Test
Imagine researchers identify a drug they believe could work against a particular childhood cancer.
The next question is obvious:
Does it actually work?
The Xenograft & Cell-Lines Core helps researchers begin answering that question.
Using carefully characterized tumor models, scientists can evaluate:
- How a tumor responds to different doses of a drug
- Whether a treatment slows or stops tumor growth
- How two or more drugs perform when used together
- Potential toxicity associated with a treatment
- Biological changes occurring inside the tumor after treatment
Researchers can also collect tumor tissue during and after experiments for additional genomic, molecular and pathological analysis.
Each experiment adds another piece to the puzzle.
A Library Built for Childhood Cancer Research
At the heart of the Core is an extensive collection of pediatric PDX models representing multiple childhood cancers.
These models provide researchers with something extraordinarily valuable: the ability to investigate potential treatments against tumors derived from actual patients.
The collection was built on pediatric PDX models developed through decades of research at Greehey CCRI and continues to grow as new models are established and characterized.
Tumor samples are carefully preserved in a biobank, tracked and accompanied by molecular and histological information that can help researchers select appropriate models for their studies.
That means an experiment doesn’t simply begin with “Let’s test this drug.”
Researchers can ask a much more important question:
“Which tumor should we test it against — and why?”
Why This Matters for Childhood Cancer
Childhood cancer isn’t one disease.
Even two children diagnosed with the same type of cancer can have tumors with important biological differences.
Some cancers respond well to existing therapies.
Others return after treatment, develop resistance or have very few effective treatment options.
Researchers need models that allow them to study those differences.
PDX models can help scientists investigate why some tumors respond while others do not and identify treatment strategies worthy of further study.
They do not guarantee that a treatment will work in a child. No laboratory model can perfectly reproduce a human patient.
Instead, they provide researchers with another critical level of evidence before deciding whether a potential therapy deserves to move farther down the long road toward clinical testing.
Connecting Discovery to Treatment
Think about the research journey we’ve highlighted throughout Childhood Cancer Awareness Month.
Scientists can use genomic sequencing to uncover what makes a cancer different.
They can use target discovery technologies to identify a possible weakness.
And then resources such as the Xenograft & Cell-Lines Core can help researchers ask the next question:
Can we turn that weakness into a treatment strategy that actually affects the tumor?
That connection between discovery and testing is essential to translational cancer research.
Because finding something interesting in a cancer cell is only the beginning.
The real goal is turning discoveries into better, safer, and more effective treatments for children with cancer.
🎗️ That is the science behind the Gold Ribbon.
Learn more about the Greehey CCRI PDX/Xenograft Core gccri.uthscsa.edu/services/pdx/